• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Zymeworks Inc.

    6/27/25 4:15:34 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    8-K
    false 0001937653 0001937653 2025-06-26 2025-06-26
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 26, 2025

     

     

    Zymeworks Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41535   88-3099146

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    108 Patriot Drive, Suite A

    Middletown, Delaware

      19709
    (Address of principal executive offices)   (Zip Code)

    (302) 274-8744

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.00001 per share   ZYME   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    Amendment to Pre-Funded Warrants

    On June 26, 2025, Zymeworks Inc. (the “Company”) entered into an amendment (the “Amendment”) to the outstanding Pre-Funded Warrants to Purchase Shares of Common Stock (the “Pre-Funded Warrants”), issued on December 28, 2023 to EcoR1 Capital Fund, L.P. (“EcoR1”) and EcoR1 Capital Fund Qualified, L.P. (together with EcoR1, the “Purchasers”) pursuant to the Securities Purchase Agreement, dated December 23, 2023, by and between the Company and the Purchasers (the “Purchase Agreement”). The Purchasers beneficially own in the aggregate more than 5% of the Company’s outstanding shares of common stock, $0.00001 par value per share (“Common Stock”). Oleg Nodelman, the manager of EcoR1 Capital LLC (“EcoR1 Capital”) (an affiliate of the Purchasers), and Scott Platshon, a partner at EcoR1 Capital, are members of the Company’s board of directors.

    The Amendment removed the limitation on exercise contained in Section 12 of the Pre-Funded Warrants, which prohibited the exercise of the Pre-Funded Warrants if, after giving effect or immediately prior to such exercise, a Purchaser, together with its affiliates and any other persons whose beneficial ownership of shares of Common Stock would be aggregated with such Purchaser for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, would beneficially own more than 19.99% of the total number of issued and outstanding shares of Common Stock or voting power of the Company following such exercise.

    The foregoing description of the material terms of the Amendment is qualified in its entirety by reference to the Amendment attached hereto as Exhibit 10.1, which is incorporated by reference herein.

     

    Item 3.02

    Unregistered Sales of Equity Securities.

    As previously disclosed in a Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on December 26, 2023, the Company entered into the Purchase Agreement with the Purchasers, pursuant to which the Purchasers purchased 5,086,521 Pre-Funded Warrants to purchase 5,086,521 shares of Common Stock. The per share purchase price for the Pre-Funded Warrants was $9.8299, for an aggregate purchase price of approximately $50 million.

    On June 26, 2025, the Purchasers net exercised the Pre-Funded Warrants in full to acquire 5,086,521 shares of the Company’s Common Stock at an exercise price of $0.0001 per share. In connection with the net exercise, on June 27, 2025, the Company issued an aggregate of 5,086,480 shares of Common Stock (the “Pre-Funded Warrant Shares”). Following the issuance of the Pre-Funded Warrant Shares, the total number of shares of the Company’s Common Stock outstanding as of June 27, 2025 is 74,844,505.

    The issuance of the Pre-Funded Warrant Shares was exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof, as a transaction involving the exchange of securities by the Company with existing holders of the Company’s securities where no commissions or other remuneration was paid or given, directly or indirectly, to any party for soliciting such exchange.


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

      

    Description

    10.1    Amendment No. 1 to Pre-Funded Warrants to Purchase Shares of Common Stock, dated June 26, 2025 by and among the Company and the Purchasers.
    104    Cover Page Interactive Data File (embedded as Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

           

    ZYMEWORKS INC.

        (Registrant)
    Date: June 27, 2025     By:  

    /s/ Kenneth Galbraith

        Name:   Kenneth Galbraith
        Title:   Chair, Chief Executive Officer and President
    Get the next $ZYME alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    11/1/2024$12.00Overweight → Equal Weight
    Wells Fargo
    3/21/2023$12.00Overweight
    Wells Fargo
    1/4/2023$10.00 → $8.00Neutral
    H.C. Wainwright
    12/20/2022$7.70 → $11.00Hold → Buy
    Jefferies
    11/1/2022$40.00 → $8.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc exercised 5,086,480 in-the-money shares at a strike of $0.00 and covered exercise/tax liability with 41 shares (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      6/27/25 5:50:21 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    See more
    • Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

      VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023,

      4/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

      VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development. With a proven track record in investment management gained over more than two de

      2/18/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Augurex Life Sciences Corp. Names Healthcare Leader Neil Klompas to Succeed Co-Founder Dr. Norma Biln as President and CEO

      Veteran life sciences executive Mr. Neil Klompas to assume role of President and CEO Co-Founder and outgoing CEO Dr. Norma Biln to helm research and new product development and remain Chair of the Board of Directors Augurex Life Sciences Corp., a world leader in the early diagnosis of autoimmune diseases and a pioneer in the field of 14-3-3η based diagnostics, today announced the appointment of Mr. Neil Klompas as President and Chief Executive Officer. Mr. Klompas will succeed Augurex's Co-founder Dr. Norma Biln, who has served as President and CEO since the Company began operations in 2008. Dr. Biln will continue to be an integral part of the company transitioning into the interim r

      8/6/24 7:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Financials

    Live finance-specific insights

    See more
    • Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentReported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 million as of December 31, 2024), which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into 2H-2027Will host conference call with management today at 4:30 p.m. Eastern Time (ET) VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to imp

      5/8/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time. The event will be webcast live with dial-in details and webcast replay

      4/17/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelinAcceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera® (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)Reported $324.2 million in cash resources as of December 31, 2024, which when combined with certain anticipated

      3/5/25 4:05:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by Zymeworks Inc.

      SCHEDULE 13D - Zymeworks Inc. (0001937653) (Subject)

      6/27/25 6:14:18 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Zymeworks Inc.

      8-K - Zymeworks Inc. (0001937653) (Filer)

      6/27/25 4:15:34 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Zymeworks Inc. (0001937653) (Filer)

      5/30/25 5:14:06 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Zymeworks

      TD Cowen initiated coverage of Zymeworks with a rating of Buy

      5/20/25 8:13:34 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Analyst with a new price target

      Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00

      12/16/24 6:40:30 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously

      11/7/24 6:47:25 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

      Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune dise

      5/30/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

      Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancerZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological Cancers Congress; trial enrollment remains on track VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunct

      5/22/25 5:00:00 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zymeworks Announces Participation in Upcoming Investor Conferences

      VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on June 4 at 2:35 pm Eastern Time (ET) in New York, NY.Goldman Sachs Global Healthcare Conference: Zymeworks' management will participate in one-on-one

      5/21/25 6:00:00 AM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      5/19/25 6:35:05 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/18/25 3:17:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

      4 - Zymeworks Inc. (0001937653) (Issuer)

      4/7/25 6:34:11 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 9:00:57 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

      SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

      11/14/24 4:27:20 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zymeworks Inc.

      SC 13G - Zymeworks Inc. (0001937653) (Subject)

      11/13/24 4:30:24 PM ET
      $ZYME
      Biotechnology: Pharmaceutical Preparations
      Health Care